Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

• Rezidiviertes/Metastasiertes Plattenepithelkarzinom des Kopf-Hals-Bereichs: Aktueller Therapiestandard und Perspektiven

  2026 Trillium Krebsmedizin article Medicine Head and Neck Cancer Studies

  0

  citations
• UV1 vaccination in pembrolizumab-treated patients with recurrent or metastatic head and neck cancer: A randomized multicenter phase 2 trial

  2025 Med article Medicine Head and Neck Cancer Studies Open access

  7

  citations
• UV1 cancer vaccine in pembrolizumab-treated patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma: results from the randomized phase 2 FOCUS trial

  2024 medRxiv preprint Medicine Cancer Immunotherapy and Biomarkers Open access

  1

  citations
• Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab – the randomized phase 2 FOCUS trial

  2024 Frontiers in Oncology article Medicine Cancer Immunotherapy and Biomarkers Open access

  11

  citations
• Stereotactic radiotherapy in the management of oligometastatic and recurrent head and neck cancer: a single-center experience

  2023 Strahlentherapie und Onkologie article Medicine Head and Neck Cancer Studies Open access

  6

  citations
• Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma

  2023 Journal of Clinical Investigation article Medicine Cancer Immunotherapy and Biomarkers Open access

  32

  citations
• NK Cell-Dependent Antibody-Mediated Immunotherapy Is Improved In Vitro and In Vivo When Combined with Agonists for Toll-like Receptor 2 in Head and Neck Cancer Models

  2021 International Journal of Molecular Sciences article Immunology and Microbiology Immune Cell Function and Interaction Open access

  8

  citations
• Prospective practice survey of management of cetuximab-related skin reactions

  2020 Supportive Care in Cancer article Medicine Chemotherapy-related skin toxicity Open access

  3

  citations
• Methotrexate plus or minus cetuximab as first‐line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib‐randomized phase II study Commence

  2020 Head & Neck article Medicine Head and Neck Cancer Studies Open access

  19

  citations

9 results